the co. has also indicated that FDA approvals is something the...

the co. has also indicated that FDA approvals is something the commercial partner would consider doing , hence the slight delay probably in working out terms , as it can be a long and expensive process, thats is why they dont want to get caught up in the wait for the US mrkt. when they can have a good revenue stream from other parts of the world, SM has been smart by controlling the manufacturing side of things as he will have a mark up on the actual cost of manufacturing , and the cost at which he supplies it to the commercial partner, they will also be looking at mile stone payments , so all in all we could be walking away with between 12-15% of total sales , so even if we take the lowest sales figures from a 4billion mrkt. and say we get 5% of the mrkt. we should still be looking at $25-30mill p/a , put that on a p/e x 10 a mrkt. cap of $250mill. thats a $2+ sp, now imagine if we got 25%-50% of the mrkt. the potential is enormous, your better of holding this stock , then thinking about getting in at 43c , its cheap as chips!!
cheers